Library / Laws / 116th Congress / Senate Bills / S. 64

S. 64

To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.

Senate · 1 version on the shelf